Drug profile · INN
ranitidine bismuth citrate
TRITEC
ranitidine bismuth citrate (TRITEC) is a histamine h2 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — ranitidine bismuth citrate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
ranitidine bismuth citrate (TRITEC) is a histamine h2 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Histamine H2 receptor antagonist
Primary target: Histamine H2 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is ranitidine bismuth citrate?
ranitidine bismuth citrate (TRITEC) is a histamine h2 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for ranitidine bismuth citrate?
TRITEC is a marketed brand name for ranitidine bismuth citrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ranitidine bismuth citrate?
ranitidine bismuth citrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.